JP6426195B2 - 治療用化合物の結晶形態及びその使用 - Google Patents

治療用化合物の結晶形態及びその使用 Download PDF

Info

Publication number
JP6426195B2
JP6426195B2 JP2016552430A JP2016552430A JP6426195B2 JP 6426195 B2 JP6426195 B2 JP 6426195B2 JP 2016552430 A JP2016552430 A JP 2016552430A JP 2016552430 A JP2016552430 A JP 2016552430A JP 6426195 B2 JP6426195 B2 JP 6426195B2
Authority
JP
Japan
Prior art keywords
less
particles
crystalline form
compound
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016552430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535779A5 (cg-RX-API-DMAC7.html
JP2016535779A (ja
Inventor
エンロウ、エリザベス
ゴエ グエン、ミン
ゴエ グエン、ミン
ゼット オング、ウィンストン
ゼット オング、ウィンストン
Original Assignee
カラ ファーマシューティカルズ インコーポレイテッド
カラ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/184,886 external-priority patent/US9353123B2/en
Application filed by カラ ファーマシューティカルズ インコーポレイテッド, カラ ファーマシューティカルズ インコーポレイテッド filed Critical カラ ファーマシューティカルズ インコーポレイテッド
Publication of JP2016535779A publication Critical patent/JP2016535779A/ja
Publication of JP2016535779A5 publication Critical patent/JP2016535779A5/ja
Application granted granted Critical
Publication of JP6426195B2 publication Critical patent/JP6426195B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2016552430A 2013-11-01 2014-11-03 治療用化合物の結晶形態及びその使用 Expired - Fee Related JP6426195B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361898741P 2013-11-01 2013-11-01
US61/898,741 2013-11-01
US14/184,886 2014-02-20
US14/184,886 US9353123B2 (en) 2013-02-20 2014-02-20 Therapeutic compounds and uses thereof
PCT/US2014/063630 WO2015066584A1 (en) 2013-11-01 2014-11-03 Crystalline forms of therapeutic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018199872A Division JP2019038824A (ja) 2013-11-01 2018-10-24 治療用化合物の結晶形態及びその使用

Publications (3)

Publication Number Publication Date
JP2016535779A JP2016535779A (ja) 2016-11-17
JP2016535779A5 JP2016535779A5 (cg-RX-API-DMAC7.html) 2017-03-16
JP6426195B2 true JP6426195B2 (ja) 2018-11-21

Family

ID=53005242

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016552430A Expired - Fee Related JP6426195B2 (ja) 2013-11-01 2014-11-03 治療用化合物の結晶形態及びその使用
JP2018199872A Pending JP2019038824A (ja) 2013-11-01 2018-10-24 治療用化合物の結晶形態及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018199872A Pending JP2019038824A (ja) 2013-11-01 2018-10-24 治療用化合物の結晶形態及びその使用

Country Status (5)

Country Link
EP (1) EP3062795A4 (cg-RX-API-DMAC7.html)
JP (2) JP6426195B2 (cg-RX-API-DMAC7.html)
AU (1) AU2014341966B2 (cg-RX-API-DMAC7.html)
CA (2) CA2928665A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015066584A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019038824A (ja) * 2013-11-01 2019-03-14 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019031902A2 (ko) 2017-08-11 2019-02-14 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
KR102518632B1 (ko) 2018-04-18 2023-04-06 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
WO2020179837A1 (en) 2019-03-04 2020-09-10 Ricoh Company, Ltd. Cooperation processing apparatus and method
GB201915447D0 (en) * 2019-10-24 2019-12-11 Johnson Matthey Plc Polymorphs of avapritinib and methods of preparing the polymorphs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
US20090036474A1 (en) * 2004-10-12 2009-02-05 Patrick Ple Quinazoline derivatives for use against cancer
US9353123B2 (en) * 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
AU2014341966B2 (en) * 2013-11-01 2017-08-17 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019038824A (ja) * 2013-11-01 2019-03-14 カラ ファーマシューティカルズ インコーポレイテッド 治療用化合物の結晶形態及びその使用

Also Published As

Publication number Publication date
EP3062795A1 (en) 2016-09-07
AU2014341966B2 (en) 2017-08-17
CA2928665A1 (en) 2015-05-07
WO2015066584A1 (en) 2015-05-07
CA3109285A1 (en) 2015-05-07
EP3062795A4 (en) 2017-05-31
JP2016535779A (ja) 2016-11-17
JP2019038824A (ja) 2019-03-14
AU2014341966A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
US11713323B2 (en) Crystalline forms of therapeutic compounds and uses thereof
JP7368661B2 (ja) 医薬組成物
JP2020015758A (ja) 改善された粘膜輸送を示す医薬用ナノ粒子
JP7058885B2 (ja) 尿素誘導体及びその使用
JP2019038824A (ja) 治療用化合物の結晶形態及びその使用
US9688688B2 (en) Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US12115246B2 (en) Compositions and methods for ophthalmic and/or other applications
US9890173B2 (en) Crystalline forms of therapeutic compounds and uses thereof
HK1228197B (en) Crystalline forms of therapeutic compounds and uses thereof
HK1228197A1 (en) Crystalline forms of therapeutic compounds and uses thereof
KR20200074179A (ko) Ret9 및 vegfr2 억제제

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180925

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181024

R150 Certificate of patent or registration of utility model

Ref document number: 6426195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees